Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 2Myocardial Reperfusion Injury 2Cardiotoxicity 2Vomiting 1Uveal Melanoma 1Thrombosis 1Substance Withdrawal Syndrome 1Retinal Diseases 1Reperfusion Injury 1Pain, Postoperative 1Opioid-Related Disorders 1Nausea 1Melanoma 1Macular Degeneration 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Choroid Diseases 1Breast Neoplasms 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × salicylhydroxamic acid × Clear all
NCT07272057 2025-12-09

SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

Shanghai Chest Hospital

Phase NA Not yet recruiting
200 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡